Phospholipids, tumour marker and beta-CrossLaps in diagnosis of gastric carcinoma.
The aim of this study was to evaluate the effectiveness of the serum tumor marker levels of CEA, CA 19-9, CA 72-4 and beta-CrossLaps in gastric cancer patients. As an additional parameter, we investigated the membrane phospholipid profile of gastric cancer patients. We measured the tumor marker and phospholipid concentrations in 40 patients suffering from gastric cancer, 12 patients suffering from pancreatitis and 40 patients with gastric ulcera. We used the Elecsys 2010 enzyme analyser to determine the concentrations of CEA, CA 19-9, CA 72-4 and beta-CrossLaps. Phospholipid fractions were determined by HPLC. Preoperative serum levels of CEA, CA 19-9 and CA 72-4 showed sensitivities of 47.5%, 68% and 76%, respectively. The sensitivity of beta-CrossLap was 63% for non-metastatic and 76% for metastatic gastric cancer. The phospholipid fraction of phosphatidyl ethanolamine showed elevated concentrations. Additional prognostic information can be obtained using the combined assay of these tumor markers in gastric cancer patients.